Abstract
The monoclonal humanized anti-HER2 antibody trastuzumab was radiolabeled with the positron emitter 76Br (T12 =16.2 h). Indirect labeling was performed using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ( 76Br-NBI) as a precursor molecule. 76Br-NBI was prepared by bromination of the 7-(p-isothiocyanato-phenyl)dodecahydro-7,8-dicarba-nido- undecaborate(1-) ion (NBI) with a yield of 93-95% using Chloramine-T (CAT) as an oxidant. Coupling of radiobrominated NBI to antibody was performed without intermediate purification, in an "one pot" reaction. An overall labeling yield of 55.7 ± 4.8% (mean ± maximum error) was achieved when 300 μg of antibody was labeled. The label was stable in vitro in physiological and denaturing conditions. In a cell binding test, trastuzumab remained immunoreactive after labeling.
Original language | English |
---|---|
Pages (from-to) | 425-433 |
Number of pages | 9 |
Journal | Nuclear Medicine and Biology |
Volume | 31 |
Issue number | 4 |
DOIs | |
Publication status | Published - May 2004 |
Externally published | Yes |
Keywords
- Bromine-76
- Monoclonal antibodies
- nido-Carborate derivatives
- Prosthetic group
- Radiobromination
- Trautzumab
ASJC Scopus subject areas
- Molecular Medicine
- Radiology Nuclear Medicine and imaging
- Cancer Research